Epithelial ovarian tumors frequently display deletions on the short arm of chromosome 3 suggesting the existence of tumor suppressor genes within the deleted regions. We have recently established a primary tissue culture system as a model to investigate the genetic events associated with ovarian cancer. The frequencies of loss of heterozygosity (LOH) at 16 loci representative of chromosome 3p in 33 tumor biopsies and 47 ovarian primary cultures derived from unselected ovarian cancers were examined. This repertoire also included benign and borderline tumors as well as malignant ovarian ascites. LOH was observed in 25 (31%) samples for at least one marker: 21 of 58 malignant, two of 12 borderline and two of 10 benign specimens. Chromosome 3p loss was not restricted to ovarian tumors of high grade and stage. LOH was observed in both cultured and non cultured tumors and ascites. A spontaneously immortalized cell line derived from a malignant ovarian ascites, OV-90, displayed LOH of the majority of markers suggesting loss of one homolog of chromosome 3p. The pattern of deletion displayed by these 25 samples enabled the determination of at least two distinct regions of overlapping deletions on chromosome 3p extending from D3S1270 to D3S1597 and from D3S1293 to D3S1283. In addition, a region proximal to D3S1300 was deleted in a subset of samples. Although loss of loci overlapping these three regions (Regions I, II and III) were observed in malignant and benign tumors, in borderline tumors loss was observed of markers representative of Region
Introduction
Ovarian cancers arising from the surface epithelium are the second most common gynecological cancer and account for nearly half of all deaths associated with gynecological related malignancies. The high mortality is mainly related to the absence of the symptoms in the majority of women in the early stages of the disease. Epithelial ovarian cancers represent 87% of all ovarian cancers and originate from either the ovarian surface epithelium (OSE) or from the crypts or inclusion cysts developed from this surface epithelium (Whitman et al., 1993) . Ovarian tumors are classi®ed according to the cell type (serous, mucinous, endometrioid, clear cell, Brenner and undierentiated or mixed histology), grade (borderline or low malignancy potential and well-to poorly dierentiated carcinomas) and stage (I ± IV) (Whitman et al., 1993) . This complexity of classi®cation re¯ects the heterogeneity of epithelial ovarian cancer.
The molecular events underlying the development of carcinomas that arise from the OSE are still largely unknown. Numerous karyotype analyses have demonstrated a number of recurrent numerical and structural anomalies associated with chromosome 3p (Pejovic et al., 1992; Whang-Peng et al., 1984; Yonescu et al., 1996) . Early studies using a limited number of polymorphic RFLP markers have revealed loss of heterozygosity (LOH) at 3p21 and at 3p22-24 (Dodson et al., 1993; Ehlen and Dubeau, 1990; Zheng et al., 1991) . On a limited number of ovarian tumors but using a large series of polymorphic microsatellite repeat markers an interstitial deletion was identi®ed on chromosome 3p21 (Jones and Nakamura, 1992) . At least one group observed that specimens exhibiting LOH distal to 3p24 correlated with the more aggressive disease (Ehlen and Dubeau, 1990; Zheng et al., 1991) . Experiments involving monochromosomic hybrids indicate that chromosome 3p is sucient for suppression of the tumorigenic phenotype in an ovarian cancer cell line (Rimessi et al., 1994) . Taken together, these results suggest that chromosome 3p plays an important role in OSE tumorigenesis and points to the presence of chromosome 3p tumor suppressors implicated in this disease.
We have previously described a primary cell culture model to study ovarian carcinogenesis (Lounis et al., 1994) . These cultured cells have been shown to re¯ect the characteristics of the original tumor cells from which they were derived and thus provide a useful resource to study the molecular events implicated in OSE cancers. Preliminary results demonstrated LOH of RFLP markers representative of chromosomal regions, 3p24 and 3p14, in primary cultures of malignant as well as borderline and benign OSE tumors (Lounis et al., 1994) . In contrast to previous reports, we conducted our analysis using a large number of polymorphic markers on an extensive repertoire of unselected epithelial ovarian tumors comprising 33 tumor biopsies and 47 primary cultures. Our study includes the analysis of chromosome 3p loci which have been shown to harbor known or suspected tumor suppressor genes: the von Hippel Lindau (VHL) gene (Crossey et al., 1994) located at 3p25-26 (Latif et al., 1993a) , RARb (Sun and Kirkpatrick, 1996) located at 3p25 (Mattei et al., 1991) , TGFBR2 (Sun et al., 1994) (Wang et al., 1995) assigned to 3p22 (Mathew et al., 1994) and PTPaseg (LaForgia et al., 1993) and FHIT (Ohta et al., 1996) which both map to 3p14.2 (Wary et al., 1993; Ohta et al., 1996) . Here we report the use of epithelial ovarian primary cultures and fresh tumor biopsies to detect and map chromosome 3p deletions using RFLP and microsatellite repeat markers. 
Results

Chromosome 3p LOH analysis in ovarian tumors
We initiated our analysis of chromosome 3p using RFLP markers speci®c for THRb (3p24) and D3S30 (3p14) loci. Representative examples of PCR/RFLP analysis at these two loci are presented in Figure 1 . The summary of this analysis is included in Figure 2 . While deletions were observed at D3S30 (3p14) in benign, borderline and malignant samples, deletions at THRb locus were restricted to malignant ovarian tumors.
To determine the minimal regions of LOH we extended the LOH analysis by using 15 polymorphic microsatellite repeat markers representative of dierent loci on chromosome 3p (Figures 2 and 3 ). All 80 cases analysed were informative for at least one marker and 25 (31%) displayed LOH of one or more of these markers. Figure 2 displays the frequency of LOH for each polymorphic marker. The frequencies of LOH ranged from 8% (for D3S1266) to 27% (for D3S30) when data was combined for all tumor samples ( Figure  2 ). LOH was observed in samples representative of solid tumors and ovarian ascites (for example, 1304T and OV-55, respectively), primary cultures of ovarian tumors or ascites (for example, TOV-192 and OV-30, respectively) and a spontaneously immortalized cell line (OV-90) ( Figure 3 ).
The pattern of allelic loss on chromosome 3p for each sample displaying LOH for at least one marker is schematically presented in Figure 3 . Three tumors (OV-90, OV-55, 1304-T) displayed LOH of the majority of informative markers analysed on chromosome 3p, suggesting complete loss of one chromosome 3p homolog. The remaining group of samples displayed a LOH pattern suggesting partial loss of one 3p homolog. Within this group of samples, the pattern of loss enabled the determination of two distinct smallest regions of overlap of deletions on chromosome 3p (Figure 3 ). Region I is de®ned by the retention of D3S1270 and of D3S1597 but loss of D3S1620 located at 3p25-pter as observed in the analysis of 1167T, for example (Figure 1 ). Region II is de®ned by the retention of markers D3S1293 and D3S1283 but loss of EABMD1/2 which represents the THRb locus at 3p24, based on results from samples Figure 2 Frequency of LOH of each polymorphic chromosome 3p marker in ovarian specimens. Genetic markers are listed in descending order from the 3pter to 3p14 according to previously published map (Dib et al., 1996; Schuler et al., 1996a, b) and more recent website updates (www.ncbi.nih.gov/science96/). Approximate physical map of markers and genes on the chromosome 3p are also shown. The black bars and arrow on the left of markers indicate the three regions of deletion de®ned in this study (Regions I, II and III from top to bottom) OV-29 and OV-30 (see Figure 1) . The third region of deletion (Region III) is de®ned by retention of D3S1300 located within intron 5 of the FHIT gene and loss of the proximal marker D3S30 as observed in several samples including OV-36, 886T, 587T and BOV-38G (summarized in Figure 3 ; and see Figure  1 ). Additional markers will have to be used to de®ne the proximal boundary.
LOH with respect to grade, stage and histopathological type LOH was compared with histopathological subtype and grade of malignancy and the results are presented in Table 1 and Figure 3 . Allelic loss was observed in 36% of malignant tumors, 17% of borderline tumors and 20% of benign OSE tumors giving an overall rate of LOH of 31%. Within the malignant tumors, LOH was not restricted to any speci®c tumors subtypes and the pattern of LOH displayed by all malignant subtypes overlapped the three regions of minimal loss. In addition nine of 28 (32%) low grade tumors (grade I and grade II) and 12 of 30 (40%) high grade tumors (grade III) displayed LOH with chromosome 3p markers. No obvious correlation between tumors of grade II and III and the pattern of LOH on chromosome 3p was evident. In particular, all three regions were deleted in a subset of these tumors, and tumors contained both extensive (involving the whole of the 3p arm) and more limited deletions. Tumors of grade I showed a more restricted pattern of deletions, with deletions being smaller and involving only Regions II and III. However, due to the limited number of samples studied (2) no conclusions can be drawn at this time. There were two subtypes of borderline tumors, serous and mucinous, and one of each subtype displayed LOH of a chromosome 3p marker. The pattern of LOH displayed by these two subtypes was identical in that loss was observed with marker D3S30 only. In benign tumors LOH was 
Discussion
We have previously described an in vitro model, based on primary ovarian cell cultures, in which to study the genetic events associated with ovarian epithelial tumors (Lounis et al., 1994) . LOH of chromosome 3p was observed in both fresh specimens and primary ovarian cultures derived from solid tumors and ascites suggesting that deletions were not due to culturing artifacts. Approximately 31% of tumors displayed LOH for at least one chromosome 3p polymorphic marker. However the highest frequency of LOH was displayed in malignant tumors (36%). The frequency of LOH we have observed is comparable to previous reports of LOH using a probe speci®c to the THRb locus (Dodson et al., 1993; Zheng et al., 1991) .
There remains some controversy as to whether deletions in chromosome 3p are associated with the aggressivity of the tumor. Previous reports have shown that chromosome 3p deletions were largely associated with the more advanced disease, as LOH was more frequently observed in high grade tumors (grade III) than low grade tumors (grade I-II) (Cheng et al., 1996; Zheng et al., 1991) . This is in contrast to another study (Dodson et al., 1993) which described chromosome 3p deletions in low grade tumors. We have observed chromosome 3p loss in both low grade (nine of 28) and high grade (12 of 30) tumors, although the highest frequency of LOH was associated with the more aggressive disease. In our study we also addressed the role of chromosome 3p in borderline ovarian tumors. LOH of D3S30 marker located at 3p13-14 (Region III) was observed in two of 12 borderline samples while previous studies found no evidence of loss in borderline tumors (Cheng et al., 1996; Dodson et al., 1993) . However LOH may have been missed in previous studies due to either the small number of samples analysed or because of the restricted focus of the markers used in LOH analysis.
The polymorphic markers used in this study were chosen based on three criteria. Markers were chosen to represent chromosome 3p regions previously described by others to be frequently deleted in cancer and loci containing known or suspected tumor supressors. Additional markers were chosen ensuring representation of chromosome 3p arm in order to de®ne all possible regions of loss. It is noteworthy that using 15 microsatellite chromosome 3p markers we did not see any evidence for microsatellite instability suggesting that mismatch repair genes play only a minor role in primary OSE cancers. Our results are consistent with those of others (Phillips et al., 1996) and microsatellite instability in ovarian cancer has only been reported in ovarian cancer cell lines in the context of acquired resistance to cisplatin (Aebi et al., 1996) .
A total of 25 specimens displayed LOH of at least one marker on chromosome 3p. Three malignant tumors displayed LOH of the majority of markers suggesting loss of one homolog of chromosome 3p. The LOH analysis of one of these samples, OV-90 which is a spontaneously immortalized ovarian cell line, is consistent with karyotype analysis which revealed a complete loss of chromosome 3p homolog (Wang et al., 1998) . The pattern of deletion displayed by the samples using 15 microsatellite markers and two RFLP markers enabled the determination of two minimal regions of deletions on chromosome 3p (Figures 2 and 3) . Our data also suggest that there is another region of deletion proximal to the FHIT locus, although the proximal boundary of Region III remains to be de®ned. These results suggest the presence of at least three genes that have a suppressive eect in ovarian tumorigenesis.
Few studies have identi®ed speci®c chromosome 3p regions deleted in ovarian tumors. An interstitial deletion on chromosome 3p21 was reported in one of four ovarian tumor samples analysed for LOH (Jones and Nakamura, 1992) . This minimal region apparently falls outside the minimal regions de®ned by our study, although the genetic location of the polymorphic markers that were used in the study in relation to location of the markers used in the present study is not known. Using microcell mediated chromosome transfer into the HEY cell line, derived from a human papillary cystadenocarcinoma of the ovary (Buick et al., 1985) , hybrids containing chromosome 3p lost the transformed phenotype (Rimessi et al., 1994) . Reversion to the transformed phenotype in some of the chromosome 3 monochromosomal cell fusion hybrids was associated with LOH of speci®c chromosome 3p loci. Comparison of the regions of LOH in the interstitially deleted hybrid with results from this study indicate that at least one of the regions described by Rimessi et al. (1994) overlaps Region I de®ned in the present study.
The minimal regions of LOH exclude many of the known or suspected suppressor genes on chromosome 3p. Region I extends from D3S1270 to D3S1597 and thus excludes the locus for the VHL tumor suppressor gene which is commonly associated with renal carcinomas (Latif et al., 1993b) . This result is in accord with a recent study which suggested that VHL inactivation is not an important event in sporadic ovarian cancer (Foster et al., 1995; Nakashima et al., 1996) . Region II extends from D3S1283 to D3S1293. This region has been previously reported to be deleted in ovarian cancer (Zheng et al., 1991) and includes the RARb locus. RARb has been shown to exert a suppressive eect in epidermoid lung cancer (Houle et al., 1994) . Experiments are in progress to address whether this gene acts as a tumor suppressor in ovarian cancer. The TGFb R2 gene assigned to 3p22 has recently been reported to harbor mutations in colon cancers displaying errors in replication repair (RER + ) (Parsons et al., 1995) . The potential role of TGFb R2 as a tumor suppressor is suggested by its ability to reduce the cloning eciency in soft agar of transfectants of the MCF7 breast cancer cell line (Parsons et al., 1995; Sun et al., 1994) . The pattern of loss displayed by our specimens excludes TGFb R2 as a candidate in ovarian tumorigenesis. Recently it has been suggested that the FHIT gene may act as a tumor suppressor in digestive tract and lung carcinogenesis (Ohta et al., 1996) . The involvement of this gene appears to be less important in the development of ovarian cancer (Hendricks et al., 1997) . Indeed, we have shown an identical pattern of FHIT expression in both normal and epithelial ovarian tumors suggesting that this gene does not play a signi®cant role in ovarian tumorigenesis (Manning et al., 1998) . In addition, the FHIT gene is located outside of the proximal boundary de®ned in Region III. Similarly, the PTPaseg gene which has been associated with lung carcinogenesis (LaForgia et al., 1991) falls outside minimal regions shown to be deleted in ovarian tumors.
Our ®ndings suggest that more than one tumor suppressor gene important for ovarian tumorigenesis is located on chromosome 3p. Future studies will focus on ®ne mapping of chromosome 3p deletions in ovarian tumors and analysis of candidate genes located within the minimal region of LOH such as RARb. In addition, the primary cultures and cell lines we have developed will allow us to address the importance of speci®c candidate genes which map to chromosome 3p in ovarian tumorigenesis.
Material and methods
Clinical material
Tumor tissues and patient-matched normal tissue or peripheral blood samples were obtained at the time of surgery from patients at the CHUM-Campus Notre-Dame (designated by a letter code and a unique patient identi®er) and the Montreal General Hospital, Montreal (assigned a unique patient number followed by the designation T). The tumors were histopathologically classi®ed according the criteria established by International Federation of Gynecology and Obstetrics (FIGO). Our collection of 80 specimens include: 58 malignant (39 solid tumors and 19 ascites), 12 borderline (10 solid tumors and two ascites) and 10 benign (nine solid tumors and one ascites) ovarian tumors. These samples were obtained from 71 patients that had not received pre-operative chemotherapy. Nine specimens were obtained from recurrent tumors in patients previously treated with platinum-based chemotherapy, only one of which (687T) displayed loss of chromosome 3p markers.
Cell culture
Primary cultures were established from benign (BOV) and malignant (TOV) tumors, and from the cellular fraction of malignant ascites¯uid (OV) of ovarian origin. Ovarian primary cultures were derived as described previously (Lounis et al., 1994) and were maintained in OSE media (Kruk et al., 1990) consisting of 50 : 50 medium 199 : 105 (Sigma) supplemented with 10% fetal bovine serum containing 2.5 mg/ml fungizone and 50 mg/ml gentamycin.
DNA extraction
DNA was extracted from solid tumor tissues, cell cultures and normal tissues or lymphocytes obtained from peripheral blood according to the method described previously (Lounis et al., 1994) .
LOH analysis
Both PCR ampli®cation of microsatellite repeat polymorphisms and RFLPs were used in LOH analysis. The PCR based RFLP assay for markers EABMD1/2, EABH1/ 2 and D3S30 has been described previously (Lounis et al., 1994) . Fifteen polymorphic microsatellite repeat markers (available through the Genome Data Base) were chosen for the analysis (Figure 2) . PCR was performed in 25 ml volume containing 100 ng of genomic DNA, 1 mCi of 35 S [dATP], 16PCR buer (Pharmacia), 200 mM each of dCTP, dGTP, and dTTP, 50 pmol of each primer and 1 unit of Taq polymerase (Pharmacia). The PCR conditions were: 948C for 15 s, 558C for 15 s and 728C for 30 s during 30 cycles. The reaction products were diluted 1 : 2 with stop buer (90% formamide, 10 mM EDTA, 10% bromophenol blue, 10% xylene cyanol) and heated at 948C for 10 min prior to loading on a 5% polyacrylamide denaturing gel. Gels were dried at 808C and autoradiographed 1 ± 3 days (Kodak XAR).
LOH was scored based on the absence or a dierence in the relative intensity of alleles in tumor compared to normal DNA (allelic imbalance). All samples positive for LOH at individual loci were analysed at least twice in independent LOH assays.
